Kura Oncology reported $5.8 million in net sales of KOMZIFTI (ziftomenib) in its first full quarter of commercialization, showing strong early adoption with 85 new patient starts and broad payer coverage over 93%. The company is advancing multiple clinical trials for ziftomenib in acute myeloid leukemia (AML), including ongoing Phase 3 frontline and combination studies, with several data readouts expected in 2026. Kura also presented promising data for its solid tumor drug darlifarnib and expects to sustain growth through commercial execution and clinical milestones. The company holds $580.8 million in cash and anticipates collaboration payments to fund development through pivotal trial results expected in 2028.
Daniel Jones, leader of the Daniel Jones Investing Group, advises selling the Schwab US Dividend Equity ETF (SCHD) because it consistently underperforms compared to market indices and carefully selected high-yield portfolios. Despite SCHD's attractiv...
Wall Street ended the holiday-shortened week higher, driven by optimism over a potential Federal Reserve interest rate cut by year-end despite weaker-than-expected June jobs data. Technology stocks rebounded early in the week amid easing U.S.-Iran te...
Ethereum's price recovered past the $1.7K resistance, rising 3.02% to $1,756, driven by strong momentum indicators like MACD and RSI. A major whale closed a $54.1 million short position, taking a $9.386 million loss and paying $36,000 in fees, reflec...
Kimberly-Clark reported broad organic sales growth driven by volume and mix, though pricing pressures persist due to low consumer sentiment. While energy prices have normalized, consumers remain value-focused, limiting pricing power. Concerns over in...
Prediction markets indicate a 70% probability that XRP will close July 2026 above $1.20, reflecting bullish sentiment despite limited upside beyond this level. Currently trading around $1.14, XRP has gained about 8.5% since early July. Traders assign...
